January 2016

Female fertility preservation: innovations and questions

Preserving the potential of becoming genetic mother should now be part of the management of infants, adolescents, and young women at risk for infertility from benign or malignant diseases.
Published
Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
Like

Authors

René Frydman, M.D., Ph.D., Michaël Grynberg, M.D., Ph.D.

Volume 105, Issue 1, Pages 4-5

Abstract

Oocyte and ovarian tissue cryopreservation represents one of the most important advances in the field of reproductive medicine and biology. Preserving a woman’s potential for becoming a genetic mother is now possible for numerous diseases that could impair female fertility either by themselves or as a result of their treatment. However, female fertility preservation is still at the pioneering level and is thus often considered an experimental treatment either from a technical standpoint or in the clinical situation in which it is discussed. As a consequence, many ethics issues are raised with fertility preservation treatment in infants, adolescents, and young women.

Read the full text at: http://www.fertstert.org/article/S0015-0282(15)02046-4/fulltext

Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 

Recommended Content